Teva Pharmaceutical Industries (TEVA) Long-Term Deferred Tax (2014 - 2026)

Teva Pharmaceutical Industries has disclosed Long-Term Deferred Tax across 13 years of filings, most recently posting $2.2 billion for Q1 2026.

• Quarterly Long-Term Deferred Tax rose 24.29% year-over-year to $2.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 billion (up 24.29% YoY) and the FY2025 annual result came in at $2.2 billion, up 21.79% from the prior year.
• Long-Term Deferred Tax steadied at $2.2 billion in Q1 2026, from $2.2 billion in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $2.2 billion in Q4 2025 and troughed at $637.0 million in Q1 2022.
• A 5-year average of $1.7 billion and a median of $1.8 billion in 2025 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2022 — Long-Term Deferred Tax surged 148.55% — and 2025, when it fell 21.06%.
• Tracing TEVA's Long-Term Deferred Tax over 5 years: stood at $1.5 billion in 2022, then advanced by 24.28% to $1.8 billion in 2023, then slipped by 0.72% to $1.8 billion in 2024, then increased by 21.79% to $2.2 billion in 2025, then dropped by 0.05% to $2.2 billion in 2026.
• Business Quant data shows TEVA's Long-Term Deferred Tax at $2.2 billion in Q1 2026, $2.2 billion in Q4 2025, and $1.6 billion in Q3 2025.